Recall report: Fresenius Kabi yanks inflammatory med Ketorolac after finding particulates in vials
The FDA on Friday announced that Fresenius Kabi USA, based in Illinois, voluntarily recalled a single lot of Ketorolac Tromethamine Injection USP 30 mg/mL. Particulate matter was found in reserve sample vials of the drug, which is used as a short-term medication to manage severe acute pain which requires analgesia at the opioid level.
Fresenius Kabi USA has received no reports of negative side effects from the lot, the FDA said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.